Psilocybin Clinical Trial Proposal for AUD/SUD: Key Discussion Points
I appreciate your interest in psilocybin research, but I must be direct: the current evidence does not support prioritizing psilocybin trials over implementing and optimizing existing FDA-approved treatments that remain severely underutilized in clinical practice. Before pursuing novel psychedelic interventions, your research agenda should address the critical implementation gap where only 2% of AUD patients receive evidence-based pharmacotherapy 1.
Current Evidence Landscape
Established Treatment Standard
The evidence-based approach for AUD/SUD requires pharmacotherapy combined with structured behavioral therapy (CBT or equivalent evidence-based modality), not usual care or nonspecific counseling 2. This combination shows consistent benefit (effect size g=0.18-0.28) over usual care plus pharmacotherapy alone 2. For AUD specifically, this means naltrexone, acamprosate, or disulfiram paired with CBT, motivational enhancement therapy, or contingency management 2.
Psilocybin Evidence: Promising but Premature
The most rigorous psilocybin trial to date showed a 13.9% reduction in heavy drinking days (9.7% vs 23.6%, p=0.01) when comparing psilocybin 25-40mg to active placebo (diphenhydramine) over 32 weeks, both combined with 12 weeks of manualized psychotherapy 3. While statistically significant, this represents only one adequately powered RCT published in 2022.
A 2025 French pilot study (n=30) reported 55% abstinence at 12 weeks with 25mg psilocybin versus 11% with 1mg control 4, but suffered from critical methodological flaws: 40% of control participants refused the second session after guessing their assignment (p=0.019), and blinding integrity was poor (93.3% correct patient guesses, 86.7% investigator guesses) 4. This essentially converted a double-blind trial into an open-label study, introducing massive expectancy bias.
Critical Gaps Your Proposal Must Address
1. Blinding and Expectancy Bias
The subjective effects of psilocybin make true blinding nearly impossible. The 2022 JAMA trial used diphenhydramine as active placebo, yet participants likely still identified their group 3. The 2025 French study's blinding failure demonstrates this is not a solved problem 4. Your protocol must:
- Justify your placebo choice with pilot data on distinguishability
- Include formal blinding assessment at multiple timepoints
- Plan statistical approaches to account for expectancy effects
- Consider active comparator designs (e.g., psilocybin vs. naltrexone+CBT) rather than placebo
2. Psychotherapy Integration Complexity
Psilocybin-assisted therapy functions as a complex intervention, not a pharmacological treatment alone 5. The therapeutic framework, dosing strategy, preparation sessions, integration work, and contextual factors all contribute to outcomes 5. Your proposal needs:
- Detailed manualization of the psychotherapy protocol (the 2022 trial used 12 weeks of combined motivational enhancement therapy and CBT) 3
- Specification of therapist training requirements and fidelity monitoring
- Clear delineation between preparation, dosing session support, and integration phases
- Justification for session number (1 vs. 2 doses) and timing
3. Comparator Selection
The most scientifically valuable trial would compare psilocybin-assisted therapy to optimized standard care (pharmacotherapy + evidence-based behavioral therapy), not to placebo 1. This addresses the real clinical question: does psilocybin add value beyond what we already have? A placebo-controlled trial only tells us if psilocybin beats doing nothing well.
4. Safety and Participant Selection
The 2022 trial excluded patients with major psychiatric disorders, other drug use disorders, and those currently in AUD treatment 3. The 2025 trial required 14-60 days post-detoxification 4. Your protocol must specify:
- Cardiovascular screening (one participant had MI 3 days before second dose, though deemed unrelated) 4
- Psychiatric exclusion criteria and screening instruments
- Medication washout requirements (particularly SSRIs/SNRIs)
- Substance use timeline requirements
- Crisis management protocols for adverse psychological reactions
5. Outcome Measures and Timeline
The 2022 trial used percentage of heavy drinking days over 32 weeks as primary outcome 3. The 2025 trial used 12-week follow-up 4. Consider:
- Timeline followback for drinking patterns (standard)
- Phosphatidylethanol (PEth) as objective biomarker 6
- Craving measures (Craving Experience Questionnaire) 4
- Depression/anxiety scales (given high comorbidity) 4
- Follow-up duration of at least 36 weeks to assess durability 3
The Implementation Gap Argument
Here's the uncomfortable truth: we have effective treatments that almost nobody receives 1. Only 2% of AUD patients get FDA-approved pharmacotherapy 1. Before investing resources in psychedelic trials, your research program should address:
- Telehealth-based prescribing models for naltrexone/acamprosate
- Long-acting injectable formulations to improve adherence
- Integration of pharmacotherapy into primary care settings
- Reducing stigma and improving access to combined pharmacotherapy + behavioral therapy
A well-designed implementation science study improving uptake of naltrexone+CBT from 2% to even 10% would impact far more patients than a successful psilocybin trial that takes 5-10 years to reach clinical practice.
If You Proceed: Study Design Recommendations
Optimal design: Randomized controlled trial comparing:
- Arm 1: Psilocybin (25mg session 1,25-40mg session 2 at weeks 4 and 8) + 12 weeks manualized psychotherapy
- Arm 2: Naltrexone 50mg daily + 12 weeks identical manualized psychotherapy
- Primary outcome: Percentage heavy drinking days, weeks 4-36
- Sample size: n=150-200 (based on 2022 trial effect size)
- Population: Treatment-seeking adults with severe AUD, 14-60 days post-detoxification, no major psychiatric comorbidity
- Key secondary outcomes: Total abstinence, PEth levels, craving, depression, cost-effectiveness
This design answers whether psilocybin adds value over existing treatment and avoids the expectancy bias problem inherent in placebo-controlled psychedelic trials.
Regulatory and Practical Considerations
- FDA IND application required for Schedule I substance
- DEA Schedule I license for storage and handling
- Specialized dosing environment: Private room, trained monitors, 6-8 hour supervision per session
- Therapist training: Specialized certification in psychedelic-assisted therapy (not yet standardized)
- Insurance coverage: None currently; budget $15,000-25,000 per participant for full protocol
- Recruitment challenges: Exclusion criteria eliminate 80-90% of screened patients 7
Bottom Line for Your Meeting
Frame your discussion around these questions:
- Why psilocybin instead of implementation research on existing treatments?
- What comparator will provide clinically meaningful data (placebo vs. active treatment)?
- How will you address the fundamental blinding problem?
- What is your psychotherapy protocol and how will you ensure fidelity?
- What is your realistic timeline to clinical impact (likely 8-12 years from trial start to potential FDA approval)?
The evidence shows psilocybin has biological plausibility and preliminary efficacy signals 3, 5, but we are at least 3-4 large RCTs away from having sufficient evidence to change clinical practice 1. Meanwhile, effective treatments remain unused. Your research agenda should justify why novel interventions take priority over implementation of existing evidence-based care.